Vascepa Decision; Approve Now or Wait for CV Outcomes?
By Catherine Shaffer
Staff Writer
Staff Writer
Monday, October 14, 2013
The FDA released briefing documents ahead of Wednesday’s Endocrinologic and Metabolic Drugs Advisory Committee meeting to consider approval of Amarin Corp.’s Vascepa as an add-on to statin therapy for patients with mixed dyslipidemia.
To continue reading subscribe now to Latest News
Learn More about Latest News
Already a subscriber? Sign In or Buy now to activate your subscription
Note: our contact information has changed
Customer Care: http://support.clarivate.com
© 2018 Clarivate Analytics.
Reproduction, reposting content is strictly prohibited.
Reproduction, reposting content is strictly prohibited.